A5018682188- Liver Disease Diagnosis and Treatment
- Diet, Metabolism, and Disease
- Liver Diseases and Immunity
- Liver Disease and Transplantation
- Hepatitis C virus research
- Pancreatitis Pathology and Treatment
- Endoplasmic Reticulum Stress and Disease
- Diet and metabolism studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Alcohol Consumption and Health Effects
- Hepatitis B Virus Studies
- Systemic Sclerosis and Related Diseases
- Radiomics and Machine Learning in Medical Imaging
- Lipid metabolism and disorders
- Drug Transport and Resistance Mechanisms
- Metabolism, Diabetes, and Cancer
- Pancreatic and Hepatic Oncology Research
- Kruppel-like factors research
- Helicobacter pylori-related gastroenterology studies
- Metabolism and Genetic Disorders
- TGF-β signaling in diseases
- Pancreatic function and diabetes
- Medical Imaging Techniques and Applications
- Statistical Methods in Clinical Trials
- Health and Medical Research Impacts
Inserm
2009-2025
Sorbonne Université
2015-2025
Assistance Publique – Hôpitaux de Paris
2008-2025
Centre de Recherche des Cordeliers
2020-2025
Fondation pour l’innovation en Cadiométabolisme et Nutrition
2015-2025
Pitié-Salpêtrière Hospital
2000-2024
Université Paris 1 Panthéon-Sorbonne
2022-2024
Centre de Recherche Saint-Antoine
2024
Université Paris Cité
1999-2023
Université Sorbonne Paris Nord
2022
It has been suggested that hepatitis C virus (HCV) and especially genotype 3 is associated with steatosis. We assess the effect of treatment peginterferon or interferon alfa-2b ribavirin on analyzed 1,428 naïve patients included in a randomized trial. A single pathologist scored steatosis at baseline 24 weeks after treatment. At baseline, was present 935 (65%), including 175 (83%) 210 versus 760 (62%) 1,218 other genotypes (P <.001). The variables logistic regression were <.001),...
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty (NAFLD), is defined as (SLD) in the presence of one or more cardiometabolic risk factor(s) and absence harmful alcohol intake. The spectrum MASLD includes steatosis, metabolic steatohepatitis (MASH, NASH), fibrosis, cirrhosis MASH-related hepatocellular carcinoma (HCC). This joint EASL-EASD-EASO guideline provides an update on definitions, prevention, screening, diagnosis treatment for...
Summary Background Non‐alcoholic steatohepatitis (NASH) is a progressive form of non‐alcoholic fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and fibrosis. In Phase 2 trial in adults NASH (NCT02912260), resmetirom, an orally administered, liver‐targeted thyroid hormone receptor‐β selective agonist, significantly reduced hepatic fat (via imaging) resolved without worsening fibrosis biopsy) significant number patients compared placebo. Aims To...
ABSTRACT Background Semaglutide, a glucagon‐like peptide‐1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction‐associated steatohepatitis (MASH). Aims To describe the trial design and baseline characteristics of ‘Effect Semaglutide Subjects with Non‐cirrhotic Non‐alcoholic Steatohepatitis’ (ESSENCE) (NCT04822181). Methods ESSENCE is two‐part, phase 3, randomised, multicentre evaluating effect subcutaneous semaglutide 2.4 mg participants biopsy‐proven MASH...
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty (NAFLD), is defined as (SLD) in the presence of one or more cardiometabolic risk factor(s) and absence harmful alcohol intake. The spectrum MASLD includes steatosis, metabolic steatohepatitis (MASH, NASH), fibrosis, cirrhosis MASH-related hepatocellular carcinoma (HCC). This joint EASL-EASD-EASO guideline provides an update on definitions, prevention, screening, diagnosis treatment for...
Connective tissue growth factor (CTGF) stimulates in vitro fibroblast proliferation and extracellular matrix synthesis. The aim of this study was to assess the role CTGF liver fibrogenesis. expression investigated both at protein mRNA level biopsies chronic diseases, experimental models fibrosis, hepatic stellate cells culture. immunostaining observed most human with significant fibrosis. An increase associated a higher score fibrosis group hepatitis C (χ 2 = 9.3; P < .01) non-hepatitis...
Wound repair in the liver induces altered gene expression stellate cells (resident mesenchymal cells) a process known as “activation.” A zinc finger transcription factor cDNA, zf9 , was cloned from rat activated vivo . Zf9 and biosynthesis are increased markedly compared with normal rats (“quiescent” cells). The is localized to nucleus perinuclear zone but not quiescent cells. mRNA also expressed widely nonhepatic adult tissues fetal liver. nucleotide sequence predicts member of Kruppel-like...
ABSTRACT Background Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease, associated with MEFV mutations. FMF patients can experience liver involvement, potentially leading to cirrhosis. Objectives This study aimed evaluate involvement in at a French tertiary centre for adult FMF. Methods We conducted an observational displaying 2 pathogenic mutations National Reference Center Autoinflammatory Diseases and Inflammatory Amyloidosis (CEREMAIA) Paris included...
Semaglutide, a glucagon-like peptide-1 receptor agonist, is candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in 2:1 ratio to receive once-weekly subcutaneous semaglutide at dose 2.4 mg placebo 240 weeks. The results planned interim analysis conducted week 72 involving first 800 are...
OBJECTIVES The noninvasive serum markers, Fibro Test–Acti Test (FT–AT), are an alternative to liver biopsy in patients with chronic hepatitis C and B. aim was use these markers a prospective study of treated lamivudine order assess the impact treatment, as well factors associated fibrosis progression. METHODS Two hundred ninety-eight were included longitudinal 50 hospitals across France. FT–AT measured at baseline, then after 6, 12, 24 months 100-mg treatment. Epidemiological, clinical,...